Starter
$149
per release
250+ outlets · 48 hrs
Industry solution · Healthcare & Biotech
Press Release Distribution for Healthcare & Biotech
Health and biotech news carries regulatory weight most wires aren't built to handle. TS Newswire routes healthcare releases through outlets that understand FDA language and clinical claims.
- typical healthcare release turnaround
- 12–24 hrs
- releases reviewed for regulatory language before send
- 100%
Healthcare and biotech news is judged by a stricter standard than almost any other category — readers, journalists and regulators are all watching for claims that overstate what a treatment, device or study actually shows. TS Newswire's health distribution track exists because most general-purpose wires don't have anyone checking that a release's regulatory and clinical claims are accurate before it goes out, and that gap creates real risk for the company issuing the release.
Trade press matters more here than in most categories, too. A biotech release that only reaches consumer news outlets misses the clinical and industry trade publications that actually influence how the announcement is received by physicians, investors and partners. Our network includes outlets covering clinical trials, medical devices and healthcare policy specifically, alongside the consumer health outlets that reach a broader audience.
Where releases go wrong
Common problems in Healthcare & Biotech distribution
Clinical claims need careful language
"Cures," "treats" and similar language can trigger editorial rejection and regulatory scrutiny if used loosely.
Regulatory status must be accurate
Outlets increasingly check whether a device or drug's stated approval status is current before publishing.
Patient data needs review
Outcome data or case studies need de-identification before distribution.
Trade press matters as much as consumer press
A generic consumer wire won't reach the clinical and biotech trade outlets that actually move healthcare news.
How it works
Our Healthcare & Biotech review process
01
Regulatory language review
Every clinical or efficacy claim is checked for a named source — a trial, a study, a regulatory filing — before it goes further.
02
Approval status verification
If the release states an FDA clearance, approval or similar regulatory status, the specific stage (e.g. 510(k) clearance vs. full approval) needs to be stated accurately, not implied.
03
Consent and de-identification check
Patient case studies or outcome data are reviewed for de-identification and documented consent before distribution.
04
Dual-track distribution
Releases go to both consumer health outlets and clinical/trade press, since the two audiences respond to different framing of the same news.
Sample outlet mix
Highest-authority outlets in the network
Healthcare & Biotech releases are placed across the wider network rather than a single vertical. These are the highest-authority outlets available; browse the full list to see everything.
| Outlet | Type | Domain authority |
|---|---|---|
| Business Insider | News site | 93 |
| Yahoo Finance | Wire | 93 |
| MarketWatch | News site | 92 |
| USA Today + 125 New network | Wire | 92 |
Editorial standards
What clears review, what doesn't
We accept
- Regulatory status (clearance or approval stage) stated accurately
- Clinical claims sourced to a named study or trial
- Spokesperson with a verifiable medical or scientific title
- De-identified patient data with documented consent
- Efficacy language that matches what the cited data actually shows
- Trade press-appropriate detail (trial phase, mechanism, indication) included
We reject
- Unsubstantiated efficacy claims ("cures," "eliminates") without trial data
- Patient testimonials without compliant consent language
- Regulatory status implied but not accurately stated
- Off-label use promotion for an approved product
Compliance detail
What FDA and clinical language actually needs to say
The single most common reason a healthcare release gets held for revision is efficacy language that outruns what the underlying data supports. Words like "cures," "eliminates" or "guarantees" attached to a treatment or device trigger both an editorial hold and, in some cases, real regulatory exposure — the FDA has taken action against companies for promotional claims that exceed their approved indications. A release should state what a trial or study actually showed, with the source cited, rather than what the company hopes readers will conclude.
Regulatory status needs the same precision. "FDA cleared" and "FDA approved" are not interchangeable — they refer to different regulatory pathways with different evidentiary bars — and a release that blurs the distinction gets sent back before distribution, not after a journalist catches it.
Pricing
Choose a tier
Recommended for Healthcare & Biotech
Regulatory-sensitive releases need editorial review time — Business tier's 12–24 hour turnaround allows for it.
Business
$349
per release
600+ outlets · 24 hrs
Premium
$649
per release
1,240+ outlets · 6 hrs
Questions
Questions specific to Healthcare & Biotech
Still unsure? Ask us anything at hello@tsnewswire.com.
-
Yes. Releases citing efficacy or outcomes are checked for a named source (study, trial, or regulatory filing) before they're queued for outlets.
Free account
See all 1,240+ outlets, pricing included.
No card, no sales call, no obligation. Search the network, preview a sample release, and decide whether to submit yourself or hand it to our team.